CITATION REPORT List of articles citing

Compassionate use of tocilizumab in severe SARS-CoV2 pneumonia

DOI: 10.1016/j.ijid.2020.10.045 International Journal of Infectious Diseases, 2021, 102, 303-30

Source: https://exaly.com/paper-pdf/78006882/citation-report.pdf

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
6	SARS-CoV-2 Induced Neurological Manifestations Entangles Cytokine Storm That Implicates For Therapeutic Strategies. <i>Current Medicinal Chemistry</i> , 2021 ,	4.3	1
5	Beneficial and harmful outcomes of tocilizumab in severe COVID-19: A systematic review and meta-analysis. <i>Pharmacotherapy</i> , 2021 , 41, 884-906	5.8	7
4	Respiratory Epithelial Cells Respond to but Provide No Cross-Protection against Virus-Induced Inflammation. <i>Viruses</i> , 2020 , 13,	6.2	1
3	An updated overview of recent advances, challenges, and clinical considerations of IL-6 signaling blockade in severe coronavirus disease 2019 (COVID-19) <i>International Immunopharmacology</i> , 2022 , 105, 108536	5.8	4
2	Biologics in COVID-19 So Far: Systematic Review. <i>Pharmaceuticals</i> , 2022 , 15, 783	5.2	O
1	Antibiotic Usage in the COVID-19 Intensive Care Unit of an Infectious Diseases Hospital from Nord-Eastern Romania. 2023 , 59, 645		О